Cheng Tai Liu

US Patent:

7239488, Jul 3, 2007

Filed:

Mar 9, 2004

Appl. No.:

10/797653

Inventors:

Li-Yan Zhu - San Jose CA, US
Kazumasa Yasuda - Sunnyvale CA, US
Cheng Yih Liu - San Jose CA, US
Winston Jose - San Jose CA, US

Assignee:

SAE Magnetics (H.K.), Ltd. - Shatin, N.T.

International Classification:

G11B 5/127
G11B 21/21
G11B 5/39

US Classification:

360323, 3602353, 2960314

Abstract:

According to an embodiment of the present invention, a slider design is presented that provides improved protection for the head/sensor of the slider. In one embodiment, the design of the slider is such that ESD protection is provided during the slider wafer process, the “back-end” processes (e. g. , when the completed slider/head is incorporated into an HGA), and during operation in a disk drive or the like. In this embodiment, a conductive film is provided that surrounds the insulating-material slider substrate. The conductive film provides a grounding path during the wafer fabrication processes. This conductive layer may be further patterned during head fabrication to provide a ground path for back-end fabrication processes. A conductive stripe may be added for discharging debris in the slider-to-disk interface.

US Patent:

8025879, Sep 27, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507044

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C07K 14/00
C07K 16/18

US Classification:

4241331, 5303873, 530395

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8080415, Dec 20, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507046

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C12M 1/00

US Classification:

435334, 4352891, 435358

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8084222, Dec 27, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507051

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435 721, 435 29

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8295882, Oct 23, 2012

Filed:

Oct 18, 2010

Appl. No.:

12/906277

Inventors:

James Fan - San Ramon CA, US
Richard Kuo - Mountain View CA, US
Cheng P. Liu - Duluth GA, US

Assignee:

AT&T Intellectual Property I, LP - Atlanta GA

International Classification:

H04B 1/38

US Classification:

455558, 455415, 455418, 4554351

Abstract:

Systems, methods, and computer program products are for managing access to a femtocell coverage area. An exemplary method includes storing in a memory component a first identifier corresponding to a subscribed service of a communication device and a second identifier corresponding to a user of the communication device, and granting access to the femtocell coverage area using the second identifier.

US Patent:

8526913, Sep 3, 2013

Filed:

Oct 8, 2012

Appl. No.:

13/647019

Inventors:

Richard Kuo - Mountain View CA, US
Cheng P Liu - Duluth GA, US

Assignee:

AT&T Intellectual Property I, L.P. - Atlanta GA

International Classification:

H04M 1/66

US Classification:

455410, 455411, 4554351

Abstract:

Systems, methods, and computer program products are for managing access to a femtocell coverage area. An exemplary method includes storing in a memory component a first identifier corresponding to a subscribed service of a communication device and a second identifier corresponding to a user of the communication device, and granting access to the femtocell coverage area using the second identifier.

US Patent:

20070225355, Sep 27, 2007

Filed:

Jun 23, 2005

Appl. No.:

11/571321

Inventors:

Cheng Liu - Richmond CA, US

Assignee:

Elixirin Corporation - Richmond CA

International Classification:

A61K 31/385
C07D 339/04
C12N 1/02
C12N 1/26

US Classification:

514440000, 435248000, 435261000, 549037000

Abstract:

This invention relates to dietary compositions and to methods for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a composition comprising a combination of carnitine, lipoic acid and polyphenol, which has the effect of enhancing metabolism and reducing oxygen species at the same time. When the composition is fed to older animals, the animals will have improved metabolism at the cellular level and a reduction of oxidative stress. The invention is also drawn to a method of oral administration of carnitine, lipoic acid and polyphenol to a mammalian host, at an effective dose necessary to affect enhanced metabolic processes and reduced oxygen species in animals including humans.

US Patent:

20090155821, Jun 18, 2009

Filed:

Jan 4, 2007

Appl. No.:

12/159827

Inventors:

John Kunich - San Leandro CA, US
Cheng Liu - Richmond CA, US

International Classification:

G01N 33/574
G01N 33/566

US Classification:

435 723, 435 72

Abstract:

Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium.